ReviewMedical science monitor : international medical journal of experimental and clinical research2026
Hybrid Molecular Imaging Using PET/CT and PET/MRI in Inflammatory Bowel Disease: Current Applications, Challenges, and Future Perspectives.
Review in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hybrid molecular imaging is increasingly recognized as a valuable tool for the precision management of inflammatory bowel disease (IBD). Driven by the treat-to-target paradigm, the noninvasive quantification of transmural inflammation and the accurate differentiation of stricture phenotypes remain key clinical challenges. Current evidence indicates that although 2-deoxy-2-¹⁸F-fluoro-D-glucose (¹⁸F-FDG) positron emission tomography (PET) can effectively quantify the overall inflammatory burden, the integration of fibroblast activation protein inhibitor (FAPI)-targeted PET imaging provides important complementary value for characterizing fibro-inflammatory remodeling and distinguishing fibrotic strictures. By combining high metabolic sensitivity with high-resolution multiparametric soft-tissue characterization, PET/magnetic resonance imaging (MRI) has demonstrated potential advantages in assessing penetrating complications and facilitating longitudinal therapeutic monitoring. Pediatric and young adult patients requiring long-term follow-up may derive substantial benefit from the reduced radiation exposure offered by integrated PET/MRI systems. To overcome conventional method limitations, including physiologic intestinal uptake and attenuation-correction artifacts, the field is actively exploring novel molecularly targeted tracers, ultra-low-dose long-axial-field-of-view whole-body systems, and artificial intelligence-based image reconstruction techniques. Given that substantial current evidence is derived from small, single-center cohorts and experimental studies, these advanced modalities currently serve as adjunctive, problem-solving tools rather than routine replacements for standard endoscopy or conventional cross-sectional imaging. This review comprehensively evaluates the clinical performance, applicability, and translational barriers of hybrid molecular imaging in IBD, underscoring the urgent need to establish standardized, multicenter consensus protocols that can guide its future implementation in individualized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.